The CT plus Bev strategy was best among the three modalities when the tumor was PD-L1-negative (PFS, 8.4/5.0/3.8 months; p < 0.0001; OS, 15.6/12.9/9.3 months; p < 0.0001, respectively). The gene discussed is CD274; the disease is neoplasm.